These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8025207)

  • 1. The use of glipizide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes.
    Selam JL; Woertz L; Lozano J; Robinson M; Chan E; Charles MA
    Autoimmunity; 1993; 16(4):281-8. PubMed ID: 8025207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term insulin therapy upon therapeutic response to glipizide.
    Schwartz SL; Fischer JS; Kipnes MS; Boyle M
    Am J Med; 1987 Sep; 83(3A):22-30. PubMed ID: 3307403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion.
    Castillô M; Scheen AJ; Paolisso G; Lefèbvre PJ
    Acta Endocrinol (Copenh); 1987 Nov; 116(3):364-72. PubMed ID: 3318259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
    Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
    Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics].
    Leblanc H; Thote A; Chatellier G; Passa P
    Diabete Metab; 1990; 16(2):93-7. PubMed ID: 2196193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
    Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA
    Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
    Simpson HC; Sturley R; Stirling CA; Reckless JP
    Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.
    Pozzilli P; Pitocco D; Visalli N; Cavallo MG; Buzzetti R; Crinò A; Spera S; Suraci C; Multari G; Cervoni M; Manca Bitti ML; Matteoli MC; Marietti G; Ferrazzoli F; Cassone Faldetta MR; Giordano C; Sbriglia M; Sarugeri E; Ghirlanda G
    Diabetologia; 2000 Aug; 43(8):1000-4. PubMed ID: 10990077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus.
    Feldman EC; Nelson RW; Feldman MS
    J Am Vet Med Assoc; 1997 Mar; 210(6):772-7. PubMed ID: 9074678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.
    Feinglos MN; Thacker CR; Lobaugh B; DeAtkine DD; McNeill DB; English JS; Bursey DL
    Diabetes Res Clin Pract; 1998 Mar; 39(3):193-9. PubMed ID: 9649951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2004 Apr; 53(4):414-22. PubMed ID: 15045685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
    Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.
    Levy J; Vandenberg M; Grunberger G
    Am J Hypertens; 1995 May; 8(5 Pt 1):445-53. PubMed ID: 7662219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
    Rosenstock J; Meisel A; Raskin P
    Am J Med; 1987 Sep; 83(3A):10-5. PubMed ID: 3307402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
    Scheen AJ; Lefebvre PJ; Luyckx AS
    Eur J Clin Pharmacol; 1984; 26(4):471-4. PubMed ID: 6376145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
    Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.